Gevorg Tamamyan on the Visionary Leadership of Thomas L. Harrison and the Expanding Global Impact P53 Inc.
Gevorg Tamamyan, Editor-in-Chief and Co-Founder of OncoDaily, shared on LinkedIn:
”Thomas L. Harrison is one of the most accomplished figures in global healthcare communications.
As Chairman Emeritus of Diversified Agency Services (DAS), a division of Omnicom Group Inc., he led the world’s largest network of marketing services and communications companies overseeing more than 5,000 clients worldwide.
P53 Inc. is a U.S.-based innovator in medical media, scientific publishing, and research — proud home of OncoDaily™, OncoDaily TV, OncoDaily Medical Journal, CancerWorld Magazine, OncoDaily Magazine, OncoDaily IO, OncoDaily GI, Hemostasis Today, Fertility News, Boston Institute for Global Rankings (BIGR), Global Cancer Movement, Yvonne Award, OncoThon™, World Health Voices and VIRO.
With a mission to be the voice of medicine and a vision to become the fastest growing, most reliable, and innovative global source of medical information — where “everyone has a space to shape the future of medicine and healthcare” — P53 Inc. continues to expand its leadership across oncology, hemostasis, fertility, and biomedical innovation.
Within five years, P53 Inc. plans to evolve into a global multichannel healthcare media technology company operating 50 active brands across key medical verticals.”
Read the full announcement in OncoDaily.
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology